Top 10 Oncology Capital Raises and Investors in the U.S. – September 16th-30th, 2025

Several interesting transactions closed in the Oncology sector over the past two weeks. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.

PIPE

1. 1. Izotropic, research and development company specializing in cancer research and early detection for breast cancer, received CAD 375,000 of development capital through a private placement.

Merger/Acquisition

2. 2. Qualigen Therapeutics, early-clinical-stage therapeutics company developing treatments for adult and pediatric cancer, was acquired by Faraday Future Intelligent Electric, SIGN Foundation, Sequoia Capital, IDG, Circle, and other investors for $41 million.

Later Stage VC

3. 3. Angiex, vascular-targeted biotherapeutics for the treatment of solid cancers and other diseases of pathological angiogenesis, raised $21.99 million of venture funding.
   4. Star Therapeutics, antibody-based therapeutics that treats serious and underserved diseases through novel biological pathways, raised $125 million of Series D venture funding in a deal led by Sanofi Ventures and Viking Global Investors.
   5. Thyme Care, oncology care platform that guides cancer patients along their cancer journey, raised $97.05 million through a combination of Series D and Series D-1 funding from CVS Health Ventures, Humana and Texas Oncology.
   6. Volastra, drug discovery and therapeutics company that treats and prevents the formation of metastatic disease, raised $30.1 million of Series A1 venture funding from B Capital Group and other investors.

Early Stage VC 

7. 7. Aarvik Therapeutics, proprietary modular platform that develops site-specific antibody-drug conjugation technology, raised venture funding.
   8. Aecor.bio, bioactive peptide therapeutics that addresses treatment resistance, raised $1.5 million of venture funding from investors.
   9. Nexo Therapeutics, molecule oncology platform that advances the development of small-molecule therapies for patients with limited treatment options, raised $52.5 million of Series A venture funding in a deal led by Versant Ventures.

Seed

10. 10. SiVEC Biotechnologies, live biotherapeutic delivery platform that advances nucleic acid and gene therapies into clinical trials, raised $3.30 million of seed funding.

#castleplacement #capitalraising #privateequity #venturecapital #investment #oncology

Gary Levy

Managing Director

Please contact me if you have any questions or would like to discuss your capital raise:

Email: glevy@castleplacement.com

(C) (516) 457-0104

Send us a message:

Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement^® does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.